Barclays lowered the firm’s price target on Novartis to CHF 85 from CHF 90 and keeps an Underweight rating on the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis reports Phase III PSMAfore trial with Pluvicto met primary endpoint
- NVS Earnings this Week: How Will it Perform?
- Novartis price target lowered to CHF 74 from CHF 80 at Berenberg
- Novartis says NATALEE analysis reinforces reduction in risk of recurrence
- Novartis’ non-tuberculous mycobacterial infection treatment gets orphan status